- 1 Title: Diagnostic Accuracy of Commercially Available Tests for Respiratory Syncytial
- 2 Virus: A Scoping Literature Review in the COVID-19 Era
- 3 **Running title (50 characters):** Diagnostic accuracy of RSV tests
- 4 **Authors:** David I. Bernstein, ^a Asuncion Mejias, ^{b,c} Barbara Rath, ^{d,e} Christopher W. Woods, ^f
- 5 and Jamie Phillips Deeter^{e,g,*}
- 6 Affiliations:
- ^aCincinnati Children's Hospital Medical Center, University of Cincinnati College of
- 8 Medicine, Cincinnati, OH, USA; ^bDepartment of Pediatrics, Division of Infectious Diseases,
- 9 Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA; ^cCenter
- 10 for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's
- Hospital, Columbus, OH, USA; ^dVienna Vaccine Safety Initiative, New Orleans, LA, USA;
- ^eESCMID Study Group for Respiratory Viruses (ESGREV), Basel, Switzerland; ^fInfectious
- 13 Diseases Division, Duke University Medical Center, Durham, NC, USA; ^gRoche Diagnostics
- 14 Corporation, Indianapolis, IN, USA
- *Address correspondence to this author at: 9115 Hague Road, Indianapolis, IN, USA, 46250-
- 16 0457. Fax: +1 317-348-4320; telephone: +1 317-220-9721; email:
- 17 <u>jamie.phillips.jp1@roche.com</u>
- 18 **Keywords:** Clinical, Infectious Disease, Molecular Diagnostics, Nucleic-Acid-Based Testing,
- 19 Point of Care Testing Systems, Viral Diseases
- 20 **Abbreviations:** RSV, respiratory syncytial virus; COVID-19, coronavirus disease 2019;
- 21 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; rRT-PCR, real-time reverse
- transcription-polymerase chain reaction; CDC, Centers for Disease Control and Prevention;
- US, United States; POC, point-of-care; CLIA, Clinical Laboratory Improvement

- 24 Amendments; CI, confidence interval; DFA, direct fluorescent antibody test; FIA,
- 25 fluorescence immunoassay; IFA, immunofluorescence assay; NR, not reported.

27

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

ABSTRACT (250/250 words) **Background:** Non-pharmaceutical interventions to prevent the spread of coronavirus disease 2019 also decreased the spread of respiratory syncytial virus (RSV) and influenza. Viral diagnostic testing in patients with respiratory tract infections (RTI) is a necessary tool for patient management; therefore, sensitive and specific tests are required. This scoping literature review evaluated the analytical validity of commercially available sample-toanswer RSV diagnostic tests in different contexts. **Content:** PubMed and Embase were queried for studies reporting on the analytical validity of tests for RSV in patients with RTI (published January 2005–January 2021). Sensitivity and specificity of RSV tests and information on study design, patient, and setting characteristics were extracted from 77 studies that met predefined inclusion criteria. A literature gap was identified for studies of RSV tests conducted in adult-only populations (5.3% of total subrecords), and in outpatient (7.5%) or household (0.8%) settings. Overall, RSV tests with analytical time >30 min had higher sensitivity (62.5–100%) versus RSV tests with analytical time \leq 30 min (25.7–100%), this sensitivity range could be partially attributed to the different modalities (antigen versus molecular) used. Molecular-based rapid RSV tests had higher sensitivity (66.7–100%) and specificity (94.3–100%) than antigen-based RSV tests (25.7– 100%; 80.3–100%). Summary: Molecular-based RSV tests should be considered for first-line use when possible,

given their high sensitivity and specificity and that adults with RTI typically have low viral load, necessitating a highly sensitive test. This review benefits healthcare professionals by summarizing the diagnostic accuracy data available for commercially available RSV tests.

IMPACT STATEMENT (100/100 words)

Viral diagnostic testing in patients with respiratory tract infection is a powerful tool for patient management. This scoping literature review included 77 studies reporting the analytical validity of commercially available respiratory syncytial virus (RSV) diagnostic tests (published January 2005–January 2021) and examined the characteristics of such studies. The data suggest that molecular-based RSV tests have higher sensitivity and specificity than antigen-based tests, thus should be considered for first-line use for timely diagnosis and to detect infections in adults with low level viral load. Future studies should investigate the diagnostic accuracy of RSV tests in adults and in outpatient/household settings.

INTRODUCTION

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

Respiratory syncytial virus (RSV) infection is responsible for a significant proportion of outpatient visits and hospitalizations in children <5 years old and is associated with substantial clinical and economic burden (1). In a recent international study across 72 countries, there was an annual mean of 20.8 million cases and 1.8 million hospital admissions for RSV infection among children <5 years old, and this was associated with \$611 million (USD) discounted direct costs (2). Once considered to be a disease of childhood, there is increasing recognition of the prevalence of RSV infection in the community dwelling (3) and hospitalized adult populations; for example, the rate of hospitalization and economic burden of hospitalized adults and the elderly (≥60 years old) with RSV infection has been shown to rival that of influenza in the United States (US) (4-6). The clinical manifestations of RSV infection vary according to the age of the patient and host susceptibility to the virus, ranging from cold symptoms to severe respiratory distress (7). Both adult and pediatric patients infected with RSV often present with non-specific, overlapping symptoms that can lead to difficulty in distinguishing it from influenza, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or other respiratory illnesses (8). Thus, empiric diagnosis is often insufficient and should be supported by viral diagnostic testing to facilitate appropriate treatment, improved surveillance, and timely infection control (9). Historically, viral culture was the gold standard technique to diagnose a productive RSV infection; however, it does not provide timely results to inform clinical management (10). Therefore, real-time reverse transcription-polymerase chain reaction (rRT-PCR), which detects the presence of the virus (active or inactive) with equal or greater sensitivity than viral culture, is often referred to as the reference/gold standard for RSV diagnosis in clinical

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

laboratories (10). There are further modalities available for the detection of RSV with variable diagnostic accuracy e.g., antigen-based testing is sensitive for detecting RSV in young children but is not sensitive enough for use in older children or adults, as per the Centers for Disease Control and Prevention (CDC) guidance, due to lower viral loads in the respiratory specimens of this group (11). Thus, rRT-PCR testing is recommended for adults with suspected RSV infection (11). Most RSV testing takes place in hospitalized patients (12) where selection bias exists towards more severe cases and pediatric patients, the age group most likely to be hospitalized due to RSV infection (13). Testing for RSV in adults by internists and general practitioners is rare, partially due to lack of awareness (14). A recent international study conducted across 15 countries reported that cases of RSV in adults ≥65 years old were notably under-represented in national surveillance programs (15). RSV testing is also limited in the younger population as shown by a prospective study in pediatric patients (≤18 years old) in Germany, which revealed that only 8.7% of patients presenting with symptoms of a respiratory tract infection underwent viral diagnostic testing during standard-of-care procedures (16). The lack of routine testing for RSV may contribute to the underestimation of disease prevalence and this has practical implications. In one study based in the emergency department of a US hospital, patients aged 6–21 years old accounted for 8.7% of the total number of RSV positive tests, whereas patients aged 22–59 years old and those aged ≥60 years old accounted for 14.0% and 10.5%, respectively (17). Viral diagnostic testing in pediatric and adult populations helps tailor patient management and the implementation of hospital infection prevention policies, as well as reduce the inappropriate use of antibiotics (18). Non-pharmaceutical interventions implemented to prevent the spread of SARS-CoV-2 have also impacted the spread of RSV and influenza virus, resulting in a larger population of potential immune-naïve populations, which could lead to an increase in disease burden for

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

future respiratory virus seasons. As a result, models predict sporadic outbreaks and an increase in the prevalence of these diseases (19). Indeed, the CDC recently released a health advisory notice warning of increased interseasonal RSV activity across the Southern US (20), and a similar interseasonal resurgence of RSV has been reported in pediatric populations in another area of the US (21), Switzerland (22), and Australia (23). Viral diagnostic testing in patients presenting with symptoms of a respiratory tract infection is a powerful tool for surveillance and patient management during such periods of interseasonal resurgence and for future respiratory virus seasons. Sample-to-answer diagnostic tests encompass technology where sample extraction, processing, and analysis are automated, and the test is often performed directly in one cartridge or analyzer. These tests are often in the form of two different modalities, a lateral flow antigen capture test or a point-of-care (POC) molecular test. Such tests offer key advantages over laboratory-based diagnostics including ease of use and faster turnaround time (24). Reducing the time needed to diagnose RSV has been shown to be beneficial in adult and pediatric populations. The duration of time to RSV diagnosis from the point of hospital admission to test result is positively correlated with length of hospital stay and antibiotic use in hospitalized adults (12). Additionally, the use of POC testing for RSV in pediatric patients has been associated with a reduction in: the use of antibiotic treatment, the need for further clinical investigations, and time spent in the emergency department (25). The Clinical Laboratory Improvement Amendments (CLIA) include federal standards that regulate US clinical laboratories performing diagnostic testing on human samples (26). As defined by CLIA, waived tests are simple tests with a low risk for an incorrect result; nonwaived testing is used to refer to moderate or high complexity tests that can only be used at clinical laboratories that meet certain quality standards (27). There are several CLIA-waived and non-waived tests available for the diagnosis of RSV. Information on the sensitivity and

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

specificity of such tests, and the patient and setting characteristics where these tests have been studied, will help healthcare professionals' decision-making on the most appropriate test to use in their practice. The objective of this scoping literature review was to evaluate the sensitivity and specificity of commercially available sample-to-answer diagnostic tests for RSV in patients with acute respiratory infection and examine the characteristics of those studies. This review also sought to identify knowledge gaps in the patient and setting characteristics where these tests have been studied. MATERIALS AND METHODS Scoping Review Design, Data Sources, and Search Strategy This scoping literature review was conducted using the Scoping Review methodology as described by Arksey and O'Malley (28) and the guidance provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (29). PubMed (https://pubmed.ncbi.nlm.nih.gov/) and Embase (https://www.embase.com/) were interrogated on January 21, 2021 using the search terms and criteria in Supplemental Table 1 to identify studies reporting on the sensitivity and specificity of commercially available sample-to-answer tests for RSV in patients with acute respiratory infection published between January 2005 and January 2021. Database searches were supplemented by manual searches and references, as appropriate. Duplicate articles and ineligible publication types (narrative reviews, editorials, case reports, addresses, biographies, comments, directories, Festschrifts, interviews, lectures, legal cases, legislation, news, newspaper article, patient education handouts, popular works) were excluded. The titles and abstracts of the remaining articles were reviewed by two independent reviewers in parallel and discrepancies were

resolved through discussion. Full-text articles were then obtained, and a second round of

screening was conducted by two reviewers working in parallel, with adjudication through discussion. Articles not meeting the inclusion criteria were excluded as necessary.

Study Selection

This scoping literature review included any peer-reviewed studies in the English language providing original data on the sensitivity and specificity of a commercially available sample-to-answer test for RSV (using any molecular or non-molecular diagnostic tools) relative to an in-house or commercial rRT-PCR, viral culture, and/or immunofluorescence assay as the reference standard in patients of any age with symptoms of a respiratory tract infection in any setting. Original research articles, systematic reviews, and meta-analyses were included in the review. Studies that used a non-commercial RSV test, studies where the RSV and reference test were not carried out in the same samples, studies in immunocompromised patients, or studies not otherwise meeting the inclusion criteria were excluded. Health economic analyses and pre-clinical research studies were also excluded.

Data Extraction

The following information was extracted, where available: RSV test sensitivity, RSV test specificity, commercial brand of RSV test, data collection (prospective vs retrospective), industry sponsorship, age group of study population (adults were defined as patients ≥18 years old), majority (>75%) specimen type, majority (>75%) setting of patient recruitment, and setting where the RSV test was performed. Any missing data were recorded as 'not reported' and included in the data synthesis. The analytical time for each test was taken from its respective manufacturer's data sheet. Rapid tests, including those that were suitable for use at the POC, were defined as having an analytical time ≤30 min. Where one article reported several relevant sensitivity and specificity values (e.g., when more than one RSV test was studied or if there was a prospective and retrospective arm of the study), then each

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

test or study arm was extracted as a 'sub-record'. Following data extraction, analysis of discordant results between the two reviewers was conducted by a third independent party and discrepancies resolved. **Data Reporting** All data handling was carried out using Microsoft Excel 365 (Microsoft Corporation). The range of sensitivity and specificity values and summary statistics were recorded including the lowest and highest value quoted for a particular RSV test from the relevant sub-records. Sensitivity and specificity ranges were not reported for RSV tests with <3 supporting subrecords. RESULTS **Literature Search Outcome** Following screening of titles and abstracts, 200 articles were subject to full-text screening and 77 studies were eventually included in the qualitative synthesis (Fig. 1). In studies reporting several relevant sensitivity and specificity values (e.g., when more than one RSV test was studied), each test was extracted as a sub-record. The 77 included studies corresponded to 133 included sub-records. Overall, the literature search detected 39 different commercially available RSV tests from 27 manufacturers, which represented a variety of technologies and analytical times (Supplemental Table 2). **Characteristics of All Included Studies and Gap Analysis** Most studies examined RSV tests with analytical time ≤30 min relative to RSV tests with analytical time >30 min (66.2% vs 33.8% of included sub-records; Table 1). The analytical times taken from the manufacturer's data sheet for each test are shown in Supplemental Table 2. Most studies assessed RSV tests in mixed (49.6% of included sub-records) or pediatric

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

(38.3%) populations, were prospective in design (62.4% of included sub-records), used rRT-PCR as the reference standard (68.4%), and were industry sponsored (65.4%; Fig. 2). In all studies evaluated, a nasopharyngeal swab was the specimen type most used (48.9% of included sub-records; Fig. 2). Most patients were recruited when they were admitted to the hospital (42.1%) or from mixed (34.6%) settings (Fig. 2). For RSV tests with analytical time ≤ 30 min, most were performed at the POC (52.3%), whereas RSV tests with analytical time >30 min were predominantly conducted in the clinical laboratory (64.4%) (Table 1). Regarding knowledge gaps in the literature, there was a notably small percentage of studies conducted in adult-only patients (5.3%), few conducted in outpatient settings (7.5%) and only one study was conducted in a household setting (Table 1). Sensitivity and Specificity of Antigen- Vs Molecular-Based RSV Tests RSV tests with analytical time ≤30 min had a greater variability in published sensitivity values (25.7–100%; Table 2) relative to RSV tests with analytical time >30 min (62.5–100%; Table 2); this is partially reflective of the different assays (antigen and molecular) used for RSV tests with analytical time ≤30 min. The range of specificity values was similar for RSV tests with analytical time \leq 30 min (80.3–100%) relative to RSV tests with analytical time >30 min (77.0–100%; Table 2). Of RSV tests with analytical time ≤30 min, 70.0% (14/20) were antigen-based, and 30.0% (6/20) were molecular tests (Supplemental Table 2). Overall, molecular RSV tests with analytical time ≤30 min had an overall higher sensitivity (66.7–100%) and specificity (94.3– 100%), relative to antigen-based RSV tests with analytical time ≤30 min (sensitivity: 25.7– 100% and specificity: 80.3–100%; Table 2). This trend for higher diagnostic accuracy in molecular- vs antigen-based RSV tests with analytical time ≤30 min was preserved in all but one of the categories (specificity in the emergency department/outpatient setting) when the

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

sensitivity and specificity ranges were broken down by patient age and setting in which the test was carried out (Table 2). The sensitivity values of molecular-based tests was highest for those that detected RSV only (93–100%), followed by RSV and influenza (66.7–100%), then multiplex (≥ 3 viruses detected) platforms (62.5–100%; all Supplemental Table 3). Such summary statistics should be interpreted with caution given the differences in sensitivity between different tests with similar modalities and analytical times e.g., the cobas[®] Influenza A/B & RSV Assay (Roche Diagnostics International Ltd) and the Xpert Xpress Flu/RSV (Cepheid) are both molecularbased tests that detect RSV and influenza in ≤30 min; however, the sensitivity range reported in the literature for each test is 94.2–100.0% and 66.7–98.1%, respectively (Supplemental Table 4). Sensitivity and Specificity of CLIA-Waived Tests for RSV There was a variety of sensitivity and specificity ranges for the 14 RSV tests included in this review that were assessed under CLIA guidance (Fig. 3). Sensitivity and specificity values for all RSV tests included in the review are shown in Supplemental Table 4. For the CLIAwaived RSV tests, there was a wide range of published sensitivity (25.7–100%) and specificity values (86.8–100%; Table 3). The test with the highest range of sensitivity values was the cobas Influenza A/B & RSV Assay (94.2% [95% confidence interval (CI) 87.9–97.9] - 100.0% [95% CI 96.07–100.0]; Table 3) and the test with the highest range of specificity values was the Xpert Xpress Flu/RSV (98.1% [95% CI 96.6–99.0] – 100% [95% CI 99.7– 100]; Table 3). **DISCUSSION** This scoping literature review summarized sensitivity and specificity values in the peerreviewed literature for commercially available sample-to-answer tests for RSV. We identified

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

a knowledge gap for studies of RSV tests conducted in adult-only populations or in outpatient or household settings. Overall, RSV tests with analytical time ≤30 min had a greater variability in published sensitivity values relative to RSV tests with analytical time >30 min, which could be partially attributed to the different diagnostic tools (antigen vs molecular) used. Molecular-based rapid RSV tests had higher sensitivity and specificity ranges than antigen-based RSV tests, which aligns with CDC guidance to use molecular testing for RSV where available (11). The results from this scoping literature review showed a notable gap in studies of diagnostic accuracy of RSV tests in adults. Utilizing viral diagnostic testing in adult patients presenting with symptoms of acute respiratory infection would improve current surveillance efforts and allow for efficient triage and treatment decisions (e.g., local infection control guidance could be followed in a timely manner). This could be particularly important for elderly patients who are at a higher risk of hospitalization and death from RSV infection compared with younger adults (30). Testing strategies for SARS-CoV-2 developed in response to the global COVID-19 pandemic have undoubtedly brought diagnostics closer to the patient. With respect to RSV, this review identified few published studies available on the diagnostic accuracy of tests in outpatient or household settings. The nasopharyngeal shedding of RSV rapidly decreases 1–3 days after the onset of symptoms (31); therefore, accessible at-home or POC testing could be a valuable tool in timely infection control. Approximately half of all studies included in this review used a nasopharyngeal swab as the majority specimen type. Notably, it has been shown that the diagnostic accuracy of some types of RSV tests is dependent upon sample type. The sensitivity and specificity of immunofluorescence-based RSV tests is higher in nasopharyngeal aspirates, relative to nasal swabs (32, 33). However, there is no difference in test performance between aspirate and swab specimens when using molecular-based RSV testing (32, 34). Additionally, mid-

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

turbinate nasal swabs have been shown to have a comparative viral load to nasopharyngeal swabs in infants <2 years old (35) and are equally sensitive for the diagnosis of multiple respiratory viruses in adults (36). The advantages of using a nasal swab rather than a nasopharyngeal aspirate/swab are that it is less invasive for the patient and easier for clinical staff to transport (32, 34). The gold standard for RSV testing, rRT-PCR, was the most used comparator assay across all the studies included in this review. The use of different reference standards has been shown to affect the calculated sensitivity and specificity value of an index test; for example, a significant increase in test sensitivity has been reported in the literature when immunofluorescence is used as the reference standard compared with rRT-PCR (37). A systematic review and meta-analysis of the sensitivity and specificity of RSV rapid antigen-based tests by Chartrand et al. reported a pooled sensitivity and specificity of 80% (95% CI 76–83) and 97% (95% CI 96–98), respectively (37). In addition, there was a large disparity observed in sensitivity of RSV tests between studies in pediatric patients (81% [95% CI 78–84]) and in adults (29% [95% CI 11–48]). In contrast, a systematic review by Bruning et al. reported that age did not affect diagnostic accuracy of RSV tests; however, this analysis only focused on three rapid RSV tests (BD Veritor System RSV, Sofia RSV FIA, and Alere BinaxNOW RSV) (38). Furthermore, while RSV rapid antigen-based tests are thought to be useful for diagnosis in infants, sensitivity values as low as 7.6% have been reported for a particular brand of rapid antigen-based test in this age group (39). In some clinical contexts, the use of multiplex tests for more than one respiratory virus may increase efficiency in triaging patients presenting with symptoms of a respiratory tract infection. Young et al. compared the turnaround time for two commercial brands of rapid tests for influenza A and B and RSV. The turnaround time for the ID NOW RSV assay and

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

the ID NOW Influenza A and B assay was 6.4–15.8 min per test result vs 21.3–22.0 min for the combined cobas Influenza A/B & RSV Assay (40). In addition to considering 'time to result' for multiplex tests, users should also pay close attention to hands-on time when implementing a new assay. Multiplex RSV tests such as the BioFire FilmArray Respiratory 2.1 Panel and the ePlex Respiratory Pathogen Panel, included in this review, can detect >20 infectious respiratory pathogens; however, these tests are not CLIA-waived and have a longer turnaround time but may be extremely valuable in patients with severe disease where rapid identification of the causative agent(s) in a simultaneous manner may be beneficial. In addition, discrepancies in sensitivity between multiplex and RSV only rRT-PCR tests have been reported in the literature; this could result in varying thresholds for different respiratory viruses between different brands of multiplex rRT-PCR tests (41). The findings from our review also showed that there are differences in the sensitivity and specificity values reported for tests for RSV only relative to multiplex tests. The evidence outlined in this paper highlights the need for healthcare professionals to consider the spectrum of respiratory disease, not just SARS-CoV-2 or influenza, and consider how viral diagnostic testing could inform their patient management and treatment decisions. If clinicians do not test for RSV, it leads to selection bias and potentially an underestimation of the prevalence of the virus. Most importantly, it could lead to inappropriate treatment for the patient. Healthcare professionals should assess the benefits and drawbacks of each RSV testing method and decide which would be most appropriate in their practice. Factors to consider include the site of testing, the location of the testing instrument, the age and immune status of the individual being tested, end user of the test, where the test results will be analyzed, the clinical significance of the results, implications for infection control, and the added value of a combination test result (40, 42).

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

One strength of this scoping review is its comprehensive and structured search strategy, which has maximized the capture of relevant information. In addition, this review has considered a broad spectrum of molecular and non-molecular RSV tests with different analytical times. An inherent limitation of scoping reviews is that the data synthesis is based on the values extracted from any given study; therefore, results may not be comparable in terms of methodology, limiting the meaningful conclusions that can be drawn from differences in the sensitivity and specificity between RSV tests from different studies. However, the purpose of this scoping review was not to analyze but to summarize the published data available. Future research should assess the sensitivity and specificity of RSV tests in adult populations and in outpatient and household settings. In addition, studies should control for selection bias and adjust for differences in settings where the RSV test was performed, seasonality, and staff utilization of RSV tests. The use of POC testing for influenza and RSV across four centers in Denmark resulted in a significant reduction in antibiotic prescription and median hospitalization time in adults (44.3 hours) and children (14.2 hours), there was also an increase in the use of antiviral treatment in adults only (18). These positive results indicate that further studies are warranted to explore the effects of testing for RSV on patient outcomes (43). In conclusion, different clinical situations (e.g., the clinical laboratory of a large hospital vs an outpatient clinic) will require different diagnostic solutions. Given the higher sensitivity and specificity of molecular-based testing over antigen-based modalities for RSV infection, rRT-PCR tests should be considered for first-line use when possible. By summarizing the sensitivity and specificity data available in the peer-reviewed literature for commercially available RSV tests, this review provides a reference point for healthcare professionals to

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

investigate which test is suitable for their practice. Presently, there are several monoclonal antibodies and vaccines in development for RSV prevention and some promising anti-viral therapeutic agents for RSV treatment (44). The concurrent use of viral diagnostic testing will be become increasingly important to identify the effectiveness and appropriateness of these products in the future. Acknowledgments The authors would like to acknowledge Melanie Yarbrough (Washington University School of Medicine, St. Louis, MO, USA) for her valuable input on the design of this literature review. Support for study design and data analysis was provided by Heather Small, PhD, Sophie Lavelle, MSc, and Claire Snowball, MSc, of Ashfield MedComms, Macclesfield, UK, an Ashfield Health Company, and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Heather Small, PhD, of Ashfield MedComms, Macclesfield, UK, an Ashfield Health Company, and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland. COBAS is a trademark of Roche. All other product names and trademarks are the property of their respective owners. **Funding** This review was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland. **Ethics approval** Ethical approval was not applicable for this review. **Author contributions**

All authors contributed to the conceptualization of the study, the writing of the original draft and reviewing and editing of subsequent manuscript drafts. DIB contributed to the formal analysis and methodology of the study. JPD contributed to the data curation and supervision of the study.

Conflicts of interest

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

DIB is a paid consultant for Roche Diagnostics. AM has received research grants from NIH, Janssen and Merck and fees for participation in advisory boards from Janssen, Sanofi-Pasteur, Merck and Roche Diagnostics. BR has received institutional funding support for research and fees for participation in advisory boards from Roche Diagnostics and Quidel. CWW has received grants from DARPA, NIH/ARLG, NIH/VTEU and Sanofi, consultant fees from bioMerieux, Biofire, Giner, Biomeme, FHI Clinical, Arena Pharmaceuticals, SeLux Diagnostics and Karius, fees from participation in a data safety monitoring board from Janssen, and fees from participation in advisory boards from Regeneron and IDbyDNA; has the following patents: biomarkers for the molecular classification of bacterial infection (issued), methods to diagnose and treat acute respiratory infections (pending), gene expression signatures useful to predict or diagnose sepsis (pending), host based molecular signatures of human infection with SARs-CoV-2 (COVID-19) (pending) and methods of identifying infectious disease and assays for identifying infectious disease (issued); holds stocks in Predigen Inc (equity, founder); is employed by Duke University and Durham VA Health Care System; and is the principal investigator for RADx UP testing Core. JPD is an employee of Roche Diagnostics Corporation.

Data availability

The data supporting this review were derived from publicly available databases.

References

394

417

Med 2007;28(2):171-81.

395 1. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial 396 virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 397 2004;22(5):275-84. Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health and economic burden 398 2. 399 of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential 400 interventions against RSV among children under 5 years in 72 Gavi-eligible countries. 401 BMC Med 2020;18(1):82. 402 3. Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, et al. Burden 403 of respiratory syncytial virus infection in community-dwelling older adults in Europe 404 (RESCEU): an international prospective cohort study. Eur Respir J 405 2020:57(4):2002688. 406 4. Malosh RE, Martin ET, Callear AP, Petrie JG, Lauring AS, Lamerato L, et al. 407 Respiratory syncytial virus hospitalization in middle-aged and older adults. J Clin 408 Virol 2017;96:37-43. 409 5. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial 410 virus infection in elderly and high-risk adults. N Engl J Med 2005;352(17):1749-59. 411 6. Ackerson B, An J, Sy LS, Solano Z, Slezak J, Tseng HF. Cost of hospitalization 412 associated with respiratory syncytial virus infection versus influenza infection in 413 hospitalized older adults. J Infect Dis 2020;222(6):962-6. 7. 414 Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a 415 comprehensive review. Clin Rev Allergy Immunol 2013;45(3):331-79. 416 8. Falsey AR. Respiratory syncytial virus infection in adults. Semin Respir Crit Care

418 9. Midgley CM, Haynes AK, Baumgardner JL, Chommanard C, Demas SW, Prill MM, 419 et al. Determining the seasonality of respiratory syncytial virus in the United States: 420 the impact of increased molecular testing. J Infect Dis 2017;216(3):345-55. 421 10. van de Pol AC, Wolfs TFW, Jansen NJG, van Loon AM, Rossen JWA. Diagnostic 422 value of real-time polymerase chain reaction to detect viruses in young children 423 admitted to the paediatric intensive care unit with lower respiratory tract infection. 424 Critical Care 2006;10(2):R61. 425 11. Centers for Disease Control and Prevention. Respiratory syncitial virus for healthcare 426 providers. https://www.cdc.gov/rsv/clinical/index.html (Accessed October 01, 2021). 427 12. Lee N, Walsh EE, Sander I, Stolper R, Zakar J, Wyffels V, et al. Delayed diagnosis of 428 respiratory syncytial virus infections in hospitalized adults: individual patient data, 429 record review analysis and physician survey in the United States. J Infect Dis 430 2019;220(6):969-79. 431 13. Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining 432 the epidemiology and burden of severe respiratory syncytial virus infection among 433 infants and children in Western countries. Infect Dis Ther 2016;5(3):271-98. 434 14. Walsh EE. Respiratory syncytial virus infection: an illness for all ages. Clin Chest 435 Med 2017;38(1):29-36. 436 15. Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, et 437 al. The global epidemiology of RSV in community and hospitalized care: findings 438 from 15 countries. Open Forum Infect Dis 2021;8(7):ofab159. 439 16. Alchikh M, Conrad T, Hoppe C, Ma X, Broberg E, Penttinen P, et al. Are we missing 440 respiratory viral infections in infants and children? Comparison of a hospital-based 441 quality management system with standard of care. Clin Microbiol Infect 442 2019;25(3):380.e9-.e16.

443 17. Leonardi GP. Evaluation of rapid, molecular-based assays for the detection of 444 respiratory syncytial virus. Intervirology 2019;62(3-4):112-5. 18. 445 Schneider UV, Holm MKA, Bang D, Petersen RF, Mortensen S, Trebbien R, et al. 446 Point-of-care tests for influenza A and B viruses and RSV in emergency departments 447 - indications, impact on patient management and possible gains by syndromic 448 respiratory testing, Capital Region, Denmark, 2018. Euro Surveill 449 2020;25(44):1900430. 450 19. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of 451 COVID-19 nonpharmaceutical interventions on the future dynamics of endemic 452 infections. Proc Natl Acad Sci U S A 2020;117(48):30547-53. 453 20. Centers for Disease Control and Prevention. Increased interseasonal respiratory 454 syncytial virus (RSV) activity in parts of the Southern United States. 455 https://emergency.cdc.gov/han/2021/pdf/CDC-HAN-443-Increased-Interseasonal-456 RSV-Activity-06.10.21.pdf (Accessed June 16, 2021). 21. 457 Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 458 pandemic. Pediatrics 2021;148(3):e2021052089. 459 22. von Hammerstein AL, Aebi C, Barbey F, Berger C, Buettcher M, Casaulta C, et al. 460 Interseasonal RSV infections in Switzerland - rapid establishment of a clinician-led 461 national reporting system (RSV EpiCH). Swiss Med Wkly 2021;151:w30057. 462 23. Foley DA, Yeoh DK, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, et al. 463 The interseasonal resurgence of respiratory syncytial virus in Australian children 464 following the reduction of coronavirus disease 2019-related public health measures. 465 Clin Infect Dis 2021;73(9):e2829-2830. 466 24. Banerjee D, Kanwar N, Hassan F, Essmyer C, Selvarangan R. Comparison of six 467 sample-to-answer influenza A/B and respiratory syncytial virus nucleic acid

- amplification assays using respiratory specimens from children. J Clin Microbiol
- 469 2018;56(11):e00930-18.
- 470 25. Barr R, Green CA, Sande CJ, Drysdale SB. Respiratory syncytial virus: diagnosis,
- 471 prevention and management. Ther Adv Infect Dis 2019;6:2049936119865798.
- 472 26. Centers for Disease Control and Prevention. About CLIA.
- https://www.cdc.gov/clia/about.html (Accessed October 01, 2021).
- 474 27. Centers for Disease Control and Prevention. Test Complexities.
- https://www.cdc.gov/clia/test-complexities.html (Accessed October 01, 2021).
- 476 28. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J
- 477 Soc Res Methodol 2005;8(1):19-32.
- 478 29. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
- 479 Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann
- 480 Intern Med 2018;169(7):467-73.
- 481 30. Watson A, Wilkinson TMA. Respiratory viral infections in the elderly. Ther Adv
- 482 Respir Dis 2021;15:1753466621995050.
- 483 31. Abels S, Nadal D, Stroehle A, Bossart W. Reliable detection of respiratory syncytial
- virus infection in children for adequate hospital infection control management. J Clin
- 485 Microbiol 2001;39(9):3135-9.
- 486 32. Sung RYT, Chan PKS, Choi KC, Yeung ACM, Li AM, Tang JW, et al. Comparative
- study of nasopharyngeal aspirate and nasal swab specimens for diagnosis of acute
- viral respiratory infection. J Clin Microbiol 2008;46(9):3073-6.
- 489 33. Macfarlane P, Denham J, Assous J, Hughes C. RSV testing in bronchiolitis: which
- 490 nasal sampling method is best? Arch Dis Child 2005;90(6):634.
- 491 34. Abu-Diab A, Azzeh M, Ghneim R, Ghneim R, Zoughbi M, Turkuman S, et al.
- Comparison between pernasal flocked swabs and nasopharyngeal aspirates for

493 detection of common respiratory viruses in samples from children. J Clin Microbiol 494 2008;46(7):2414-7. 495 35. Blaschke AJ, McKevitt M, Ampofo K, Lewis T, Chai H, Guo Y, et al. A mid-496 turbinate swab appears comparable to nasopharyngeal swabs for quantitative 497 detection of RSV in infants. Open Forum Infect Dis 2017;4(Suppl 1):S354-S5. 498 36. Larios OE, Coleman BL, Drews SJ, Mazzulli T, Borgundvaag B, Green K, et al. Self-499 collected mid-turbinate swabs for the detection of respiratory viruses in adults with 500 acute respiratory illnesses. PLoS One 2011;6(6):e21335. 501 37. Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic accuracy of rapid 502 antigen detection tests for respiratory syncytial virus infection: systematic review and 503 meta-analysis. J Clin Microbiol 2015;53(12):3738-49. 504 38. Bruning AHL, Leeflang MMG, Vos J, Spijker R, de Jong MD, Wolthers KC, et al. 505 Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a 506 systematic review and meta-analysis. Clin Infect Dis 2017;65(6):1026-32. 39. 507 Zuurbier RP, Bont LJ, Langedijk AC, Hamer M, Korsten K, Drysdale SB, et al. Low Sensitivity of BinaxNOW RSV in Infants. J Infect Dis 2020;222(Suppl 7). 508 509 40. Young S, Phillips J, Griego-Fullbright C, Wagner A, Jim P, Chaudhuri S, et al. 510 Molecular point-of-care testing for influenza A/B and respiratory syncytial virus: 511 comparison of workflow parameters for the ID Now and cobas Liat systems. J Clin 512 Pathol 2020;73(6):328-34. 513 41. Alchikh M, Conrad T, Hoppe C, Ma X, Broberg E, Penttinen P, et al. Are we missing 514 respiratory viral infections in infants and children? Comparison of a hospital-based 515 quality management system with standard of care. Clin Microbiol Infect 516 2019;25(3):e9-.e16.

517 42. Kosack CS, Page A-L, Klatser PR. A guide to aid the selection of diagnostic tests. 518 Bull World Health Organ 2017;95(9):639-45. 519 43. Bordley WC, Viswanathan M, King VJ, Sutton SF, Jackman AM, Sterling L, et al. 520 Diagnosis and testing in bronchiolitis: a systematic review. Arch Pediatr Adolesc Med 521 2004;158(2):119-26. 522 44. Domachowske JB, Anderson EJ, Goldstein M. The future of respiratory syncytial 523 virus disease prevention and treatment. Infect Dis Ther 2021;10(Suppl 1):47-60. 524 45. Bell JJ, Anderson EJ, Greene WH, Romero JR, Merchant M, Selvarangan R. 525 Multicenter clinical performance evaluation of BD VeritorTM system for rapid 526 detection of respiratory syncytial virus. J Clin Virol 2014;61(1):113-7. 527 46. Bruning AHL, de Kruijf WB, van Weert H, Willems WLM, de Jong MD, Pajkrt D, et 528 al. Diagnostic performance and clinical feasibility of a point-of-care test for 529 respiratory viral infections in primary health care. Fam Pract 2017;34(5):558-63. 530 47. Cantais A, Mory O, Plat A, Giraud A, Pozzetto B, Pillet S. Analytical performances 531 of the BD VeritorTM System for the detection of respiratory syncytial virus and 532 influenzaviruses A and B when used at bedside in the pediatric emergency department. 533 J Virol Methods 2019;270:66-9. 534 48. Jonckheere S, Verfaillie C, Boel A, Van Vaerenbergh K, Vanlaere E, Vankeerberghen 535 A, et al. Multicenter evaluation of BD Veritor System and RSV K-SeT for rapid 536 detection of respiratory syncytial virus in a diagnostic laboratory setting. Diagn 537 Microbiol Infect Dis 2015;83(1):37-40. 538 49. Kanwar N, Hassan F, Nguyen A, Selvarangan R. Head-to-head comparison of the 539 diagnostic accuracies of BD VeritorTM System RSV and Quidel® Sofia® RSV FIA 540 systems for respiratory syncytial virus (RSV) diagnosis. J Clin Virol 2015;65:83-6.

541 50. Leonardi GP, Wilson AM, Dauz M, Zuretti AR. Evaluation of respiratory syncytial 542 virus (RSV) direct antigen detection assays for use in point-of-care testing. J Virol 543 Methods 2015;213:131-4. 51. 544 Schwartz RH, Selvarangan R, Zissman EN. BD Veritor System respiratory syncytial 545 virus rapid antigen detection test: point-of-care results in primary care pediatric 546 offices compared with reverse transcriptase polymerase chain reaction and viral 547 culture methods. Pediatr Emerg Care 2015;31(12):830-4. 548 52. Borek AP, Clemens SH, Gaskins VK, Aird DZ, Valsamakis A. Respiratory syncytial 549 virus detection by Remel Xpect, Binax Now RSV, direct immunofluorescent staining, 550 and tissue culture. J Clin Microbiol 2006;44(3):1105-7. 551 53. Cruz AT, Cazacu AC, Greer JM, Demmler GJ. Performance of a rapid assay (Binax 552 NOW) for detection of respiratory syncytial virus at a children's hospital over a 3-year 553 period. J Clin Microbiol 2007;45(6):1993-5. 554 54. Jung BK, Choi SH, Lee JH, Lee J, Lim CS. Performance evaluation of four rapid 555 antigen tests for the detection of respiratory syncytial virus. J Med Virol 556 2016;88(10):1720-4. 557 55. Khanom AB, Velvin C, Hawrami K, Schutten M, Patel M, Holmes MV, et al. 558 Performance of a nurse-led paediatric point of care service for respiratory syncytial 559 virus testing in secondary care. J Infect 2011;62(1):52-8. 560 56. Liao RS, Tomalty LL, Majury A, Zoutman DE. Comparison of viral isolation and 561 multiplex real-time reverse transcription-PCR for confirmation of respiratory 562 syncytial virus and influenza virus detection by antigen immunoassays. J Clin 563 Microbiol 2009;47(3):527-32. 564 57. Miernyk K, Bulkow L, DeByle C, Chikoyak L, Hummel KB, Hennessy T, et al. 565 Performance of a rapid antigen test (Binax NOW® RSV) for diagnosis of respiratory

| 566 | | syncytial virus compared with real-time polymerase chain reaction in a pediatric |
|-----|-----|--|
| 567 | | population. J Clin Virol 2011;50(3):240-3. |
| 568 | 58. | Moesker FM, van Kampen JJA, Aron G, Schutten M, van de Vijver D, Koopmans |
| 569 | | MPG, et al. Diagnostic performance of influenza viruses and RSV rapid antigen |
| 570 | | detection tests in children in tertiary care. J Clin Virol 2016;79:12-7. |
| 571 | 59. | Rack-Hoch AL, Laniado G, Hübner J. Comparison of influenza and RSV diagnostic |
| 572 | | from nasopharyngeal swabs by rapid fluorescent immunoassay (Sofia system) and |
| 573 | | rapid bedside testing (BinaxNOW) vs. conventional fluorescent immunoassay in a |
| 574 | | German university children's hospital. Infection 2017;45(4):529-32. |
| 575 | 60. | Selvarangan R, Abel D, Hamilton M. Comparison of BD Directigen EZ RSV and |
| 576 | | Binax NOW RSV tests for rapid detection of respiratory syncytial virus from |
| 577 | | nasopharyngeal aspirates in a pediatric population. Diagn Microbiol Infect Dis |
| 578 | | 2008;62(2):157-61. |
| 579 | 61. | Sun Y, Deng J, Qian Y, Zhu R, Wang F, Tian R, et al. Laboratory evaluation of rapid |
| 580 | | antigen detection tests for more-sensitive detection of respiratory syncytial virus |
| 581 | | antigen. Jpn J Infect Dis 2019;72(6):394-8. |
| 582 | 62. | Voermans JJ, Seven-Deniz S, Fraaij PL, van der Eijk AA, Koopmans MP, Pas SD. |
| 583 | | Performance evaluation of a rapid molecular diagnostic, MultiCode based, sample-to- |
| 584 | | answer assay for the simultaneous detection of Influenza A, B and respiratory |
| 585 | | syncytial viruses. J Clin Virol 2016;85:65-70. |
| 586 | 63. | Allen AJ, Gonzalez-Ciscar A, Lendrem C, Suklan J, Allen K, Bell A, et al. Diagnostic |
| 587 | | and economic evaluation of a point-of-care test for respiratory syncytial virus. ERJ |
| 588 | | Open Res 2020;6(3):00018-2020. |

589 64. Banerjee D, Kanwar N, Hassan F, Lankachandra K, Selvarangan R. Comparative 590 analysis of four sample-to-answer influenza A/B and RSV nucleic acid amplification assays using adult respiratory specimens. J Clin Virol 2019;118:9-13. 591 592 65. Gibson J, Schechter-Perkins EM, Mitchell P, Mace S, Tian Y, Williams K, et al. 593 Multi-center evaluation of the cobas(®) Liat(®) Influenza A/B & RSV assay for rapid 594 point of care diagnosis. J Clin Virol 2017;95:5-9. 595 66. Gosert R, Naegele K, Hirsch HH. Comparing the Cobas Liat Influenza A/B and 596 respiratory syncytial virus assay with multiplex nucleic acid testing. J Med Virol 597 2019;91(4):582-7. 598 67. Verbakel JY, Matheeussen V, Loens K, Kuijstermans M, Goossens H, Ieven M, et al. 599 Performance and ease of use of a molecular point-of-care test for influenza A/B and 600 RSV in patients presenting to primary care. Eur J Clin Microbiol Infect Dis 601 2020;39(8):1453-60. 602 68. Schnee SV, Pfeil J, Ihling CM, Tabatabai J, Schnitzler P. Performance of the Alere i 603 RSV assay for point-of-care detection of respiratory syncytial virus in children. BMC 604 Infect Dis 2017;17(1):767. 605 69. Hassan F, Hays LM, Bonner A, Bradford BJ, Franklin R, Jr., Hendry P, et al. 606 Multicenter clinical evaluation of the Alere i respiratory syncytial virus isothermal 607 nucleic acid amplification assay. J Clin Microbiol 2018;56(3):e01777-17. 70. 608 Peters RM, Schnee SV, Tabatabai J, Schnitzler P, Pfeil J, Evaluation of Alere i RSV 609 for rapid detection of respiratory syncytial virus in children hospitalized with acute 610 respiratory tract infection. J Clin Microbiol 2017;55(4):1032-6. 611 71. Freeman MC, Haddadin Z, Lawrence L, Piya B, Krishnaswami S, Faouri S, et al. 612 Utility of RSV rapid diagnostic assays in hospitalized children in Amman, Jordan. J

613

Med Virol 2020;93:3420-7.

614 72. Mesquita FDS, Oliveira DBL, Crema D, Pinez CMN, Colmanetti TC, Thomazelli LM, 615 et al. Rapid antigen detection test for respiratory syncytial virus diagnosis as a 616 diagnostic tool. J Pediatr (Rio J) 2017;93(3):246-52. 617 73. Rath B, Tief F, Obermeier P, Tuerk E, Karsch K, Muehlhans S, et al. Early detection 618 of influenza A and B infection in infants and children using conventional and 619 fluorescence-based rapid testing. J Clin Virol 2012;55(4):329-33. 620 74. Gomez S, Prieto C, Folgueira L. A prospective study to assess the diagnostic 621 performance of the Sofia(®) Immunoassay for influenza and RSV detection. J Clin 622 Virol 2016;77:1-4. 623 75. Tran LC, Tournus C, Dina J, Morello R, Brouard J, Vabret A. SOFIA(®)RSV: 624 prospective laboratory evaluation and implementation of a rapid diagnostic test in a 625 pediatric emergency ward. BMC Infect Dis 2017;17(1):452. 626 76. Tuttle R, Weick A, Schwarz WS, Chen X, Obermeier P, Seeber L, et al. Evaluation of 627 novel second-generation RSV and influenza rapid tests at the point of care. Diagn 628 Microbiol Infect Dis 2015;81(3):171-6. 629 77. Cohen DM, Kline J, May LS, Harnett GE, Gibson J, Liang SY, et al. Accurate PCR 630 detection of influenza A/B and respiratory syncytial viruses by use of Cepheid Xpert 631 Flu+RSV Xpress assay in point-of-care settings: comparison to Prodesse ProFlu. J 632 Clin Microbiol 2018;56(2):e01237-17. 633 78. Haigh J, Cutino-Moguel MT, Wilks M, Welch CA, Melzer M. A service evaluation of 634 simultaneous near-patient testing for influenza, respiratory syncytial virus, 635 Clostridium difficile and norovirus in a UK district general hospital. J Hosp Infect 636 2019;103(4):441-6. 637 79. Wabe N, Lindeman R, Post JJ, Rawlinson W, Miao M, Westbrook JI, et al. Cepheid 638 Xpert(®) Flu/RSV and Seegene Allplex(TM) RP1 show high diagnostic agreement for

639 the detection of influenza A/B and respiratory syncytial viruses in clinical practice. 640 Influenza Other Respir Viruses 2021;15:245-53. 641 80. Zou X, Chang K, Wang Y, Li M, Zhang W, Wang C, et al. Comparison of the 642 Cepheid Xpert Xpress Flu/RSV assay and commercial real-time PCR for the detection 643 of influenza A and influenza B in a prospective cohort from China. Int J Infect Dis 644 2019;80:92-7. 645 81. Ginocchio CC, Swierkosz E, McAdam AJ, Marcon M, Storch GA, Valsamakis A, et 646 al. Multicenter study of clinical performance of the 3M Rapid Detection RSV test. J 647 Clin Microbiol 2010;48(7):2337-43. 648 82. Munjal I, Gialanella P, Goss C, McKitrick JC, Avner JR, Pan Q, et al. Evaluation of 649 the 3M rapid detection test for respiratory syncytial virus (RSV) in children during the 650 early stages of the 2009 RSV season. J Clin Microbiol 2011;49(3):1151-3. 651 83. Juretschko S, Mahony J, Buller RS, Manji R, Dunbar S, Walker K, et al. Multicenter 652 clinical evaluation of the Luminex Aries Flu A/B & RSV assay for pediatric and adult 653 respiratory tract specimens. J Clin Microbiol 2017;55(8):2431-8. 654 84. Huang HS, Tsai CL, Chang J, Hsu TC, Lin S, Lee CC. Multiplex PCR system for the 655 rapid diagnosis of respiratory virus infection: systematic review and meta-analysis. 656 Clin Microbiol Infect 2018;24(10):1055-63. 657 85. Leber AL, Everhart K, Daly JA, Hopper A, Harrington A, Schreckenberger P, et al. 658 Multicenter evaluation of BioFire FilmArray Respiratory Panel 2 for detection of 659 viruses and bacteria in nasopharyngeal swab samples. J Clin Microbiol 660 2018;56(6):e01945-17. 661 86. Vos LM, Riezebos-Brilman A, Schuurman R, Hoepelman AIM, Oosterheert JJ. 662 Syndromic sample-to-result PCR testing for respiratory infections in adult patients.

663

Neth J Med 2018;76(6):286-93.

| 664 | 87. | Aslanzadeh J, Zheng X, Li H, Tetreault J, Ratkiewicz I, Meng S, et al. Prospective |
|-----|-----|--|
| 665 | | evaluation of rapid antigen tests for diagnosis of respiratory syncytial virus and |
| 666 | | human metapneumovirus infections. J Clin Microbiol 2008;46(5):1682-5. |
| 667 | 88. | Vaz-de-Lima LR, Souza MC, Matsumoto T, Hong MA, Salgado MM, Barbosa ML, et |
| 668 | | al. Performance of indirect immunofluorescence assay, immunochromatography assay |
| 669 | | and reverse transcription-polymerase chain reaction for detecting human respiratory |
| 670 | | syncytial virus in nasopharyngeal aspirate samples. Mem Inst Oswaldo Cruz |
| 671 | | 2008;103(5):463-7. |
| 672 | 89. | Goodrich JS, Miller MB. Comparison of Cepheid's analyte-specific reagents with BD |
| 673 | | directigen for detection of respiratory syncytial virus. J Clin Microbiol |
| 674 | | 2007;45(2):604-6. |
| 675 | 90. | Babady NE, England MR, Jurcic Smith KL, He T, Wijetunge DS, Tang YW, et al. |
| 676 | | Multicenter evaluation of the ePlex Respiratory Pathogen Panel for the detection of |
| 677 | | viral and bacterial respiratory tract pathogens in nasopharyngeal swabs. J Clin |
| 678 | | Microbiol 2018;56(2):e01658-17. |
| 679 | 91. | Sam SS, Caliendo AM, Ingersoll J, Abdul-Ali D, Hill CE, Kraft CS. Evaluation of |
| 680 | | performance characteristics of Panther Fusion Assays for detection of respiratory |
| 681 | | viruses from nasopharyngeal and lower respiratory tract specimens. J Clin Microbiol |
| 682 | | 2018;56(8):e00787-18. |
| 683 | 92. | Pichon M, Valette M, Schuffenecker I, Billaud G, Lina B. Analytical performances of |
| 684 | | the Panther Fusion System for the detection of respiratory viruses in the French |
| 685 | | National Reference Centre of Lyon, France. Microorganisms 2020;8(9):1371. |
| 686 | 93. | Stellrecht KA, Cimino JL, Wilson LI, Maceira VP, Butt SA. Panther Fusion® |
| 687 | | respiratory virus assays for the detection of influenza and other respiratory viruses. J |
| 688 | | Clin Virol 2019;121:104204. |

94. 689 Voermans JJC, Mulders D, Pas SD, Koopmans MPG, van der Eijk AA, Molenkamp 690 R. Performance evaluation of the Panther Fusion® respiratory tract panel. J Clin Virol 691 2020;123:104232. 692 95. Landry ML, Ferguson D. Comparison of Simplexa Flu A/B & RSV PCR with 693 cytospin-immunofluorescence and laboratory-developed TaqMan PCR in 694 predominantly adult hospitalized patients. J Clin Microbiol 2014;52(8):3057-9. 695 696

TABLES

| Table 1. Characteristics of all included studies. | | | | | | | | |
|---|--|---|---|--|--|--|--|--|
| Study characteristic | RSV tests with analytical time ≤30 min, n (%) | RSV tests with analytical time >30 min, n (%) | Total sub- records ^a , n (%) | | | | | |
| Number of sub-records | 88 (66.2) | 45 (33.8) | 133 (100.0) | | | | | |
| Commercial index $test^b$ | | | | | | | | |
| 3M Rapid Detection RSV | 4 (4.5) | _ | 4 (3.0) | | | | | |
| Test | | | | | | | | |
| Aries Flu A/B & RSV | - | 4 (8.9) | 4 (3.0) | | | | | |
| Assay | | | | | | | | |
| BD Veritor System RSV | 9 (10.2) | - | 9 (6.8) | | | | | |
| Alere BinaxNOW RSV | 14 (15.9) | - | 14 (10.5) | | | | | |
| BioFire FilmArray | - | 4 (8.9) | 4 (3.0) | | | | | |
| Respiratory 2.1 Panel | | | | | | | | |
| cobas Influenza A/B & | 10 (11.4) | - | 10 (7.5) | | | | | |
| RSV Assay | | | | | | | | |
| Directigen EZ RSV | 8 (9.1) | - | 8 (6.0) | | | | | |
| ePlex Respiratory | _ | 3 (6.7) | 3 (2.3) | | | | | |
| Pathogen Panel | | | | | | | | |
| ID NOW RSV c | 5 (5.7) | - | 5 (3.8) | | | | | |
| mariPOC Respi test | - | 4 (8.9) | 4 (3.0) | | | | | |
| Panther Fusion Flu | _ | 7 (15.6) | 7 (5.3) | | | | | |
| | | | | | | | | |

| A/B/RSV Assay | | | |
|------------------------|-----------|-----------|-----------|
| QuickVue RSV | 4 (4.5) | - | 4 (3.0) |
| RSV Respi-Strip | 3 (3.4) | _ | 3 (2.3) |
| Simplexa Flu A/B & RSV | - | 3 (6.7) | 3 (2.3) |
| Sofia RSV FIA | 11 (12.5) | _ | 11 (8.3) |
| Xpert Flu/RSV XC | 3 (3.4) | _ | 3 (2.3) |
| Xpert Xpress Flu/RSV | 6 (6.8) | _ | 6 (4.5) |
| Data collection | | | |
| Prospective | 64 (72.7) | 19 (42.2) | 83 (62.4) |
| Retrospective | 17 (19.3) | 16 (35.6) | 33 (24.8) |
| Mixed | 7 (8.0) | 10 (22.2) | 17 (12.8) |
| Population | | | |
| Adults (≥18 years) | 1 (1.1) | 6 (13.3) | 7 (5.3) |
| Children (<18 years) | 43 (48.9) | 8 (17.8) | 51 (38.3) |
| Mixed | 41 (46.6) | 25 (55.6) | 66 (49.6) |
| Not reported | 3 (3.4) | 6 (13.3) | 9 (6.8) |
| Comparator test | | | |
| DFA/IFA | 9 (10.3) | 3 (6.7) | 12 (9.0) |
| rRT-PCR | 58 (65.9) | 33 (73.3) | 91 (68.4) |
| Viral culture | 5 (5.7) | 2 (4.4) | 7 (5.3) |
| Mixed | 16 (18.2) | 5 (11.1) | 21 (15.8) |
| Other ^d | 0 | 2 (4.4) | 2 (1.5) |
| Industry sponsorship | | | |
| Yes | 52 (59.1) | 35 (77.8) | 87 (65.4) |
| No | 23 (26.1) | 7 (15.6) | 30 (22.6) |

| Not reported | 13 (14.8) | 3 (6.7) | 16 (12.0) |
|-------------------------|-----------|-----------|-----------|
| Majority specimen type | | | |
| Nasopharyngeal aspirate | 22 (25.0) | 6 (13.3) | 28 (21.1) |
| or wash | | | |
| Nasopharyngeal swab | 43 (48.9) | 22 (48.9) | 65 (48.9) |
| Nasopharyngeal aspirate | 1 (1.1) | 0 | 1 (0.8) |
| or swab | | | |
| Nasopharyngeal specimen | 1 (1.1) | - | 1 (0.8) |
| Nasal aspirate or wash | 4 (4.5) | 1 (2.2) | 5 (3.8) |
| Nasal swab | 1 (1.1) | 0 | 1 (0.8) |
| Mixed | 16 (18.2) | 16 (35.6) | 32 (24.1) |
| Setting of patient | | | |
| recruitment | | | |
| Emergency department | 5 (5.7) | 4 (8.9) | 9 (6.8) |
| Hospital | 35 (39.8) | 21 (46.7) | 56 (42.1) |
| Household | 0 | 1 (2.2) | 1 (0.8) |
| Outpatient | 5 (5.7) | 5 (11.1) | 10 (7.5) |
| Mixed | 37 (42.0) | 9 (20.0) | 46 (34.6) |
| Not reported | 6 (6.8) | 5 (11.1) | 11 (8.3) |
| Setting where test was | | | |
| performed | | | |
| Clinical laboratory | 26 (29.5) | 29 (64.4) | 55 (41.4) |
| POC | 46 (52.3) | 5 (11.1) | 51 (38.3) |
| Research laboratory | 2 (2.3) | 2 (4.4) | 4 (3.0) |
| Mixed | 10 (11.4) | 0 | 10 (7.5) |
| | | | |

Not reported 4 (4.5) 9 (20.0) 13 (9.8)

"Where one article reported several relevant sensitivity and specificity values (e.g., when more than one index test was studied), then each set of sensitivity and specificity values was extracted as a 'sub-record'; 77 included studies corresponded to 133 included sub-records.

b*Only RSV tests with ≥3 sub-records were included in the table. The following index tests had two supporting sub-records: CLART PneumoVir, nCounter, NxTAG-Respiratory Pathogen Panel, MultiCode-PLx Respiratory Viral Panel, QIAstat-Dx Respiratory Panel, Simprova-RV, NucliSens EasyQ Respiratory Syncytial Virus A+B assay, Thermo Electron RSV OIA kit, Verigene Respiratory Virus Plus Nucleic Acid Test. The following index tests had one supporting sub-record: Allplex Respiratory Panel 1, Colloidal Gold Genesis, GenRead RSV, Humasis RSV Antigen Test, Magicplex RV Panel Real-Time Test, Prodesse ProFlu+ Assay, RSV K-SeT, Seeplex RV15 OneStep ACE Detection, Bioline RSV, Solana RSV + hMPV, Speed-Oligo RSV, TRU RSV, Xpect RSV.

^cThe ID NOW RSV was formerly known as the Alere i RSV.

698

699

d'Other' comparator test was the consensus result for all three index tests studied (i.e., a ratio of 2:1 positive to negative results was considered a positive result and vice versa). DFA, direct fluorescent antibody test; FIA, fluorescence immunoassay; IFA, immunofluorescence assay; POC, point-of-care; RSV, respiratory syncytial virus; rRT-PCR, real-time reverse transcription-polymerase chain reaction.

| Table 2. Sensitivity and specificity of RSV tests by assay technology in all included | | | | | | | | | |
|---|------------------------|--------------------------------|------------------------|--|--|--|--|--|--|
| studies. | | | | | | | | | |
| | RSV tests with ≤30 mir | RSV tests with analytical time | | | | | | | |
| | | - (00) | $>30 \min (n = 45)$ | | | | | | |
| Method | Antigen | Molecular | Molecular | | | | | | |
| Number of sub- | 61 (69.3) | 27 (30.7) | 41 (91.1) ^a | | | | | | |
| records, n (%) | | | | | | | | | |
| Overall | | | | | | | | | |
| Sensitivity, % | 25.7–100 | 66.7–100 | 62.5–100 | | | | | | |
| Specificity, % | 80.3–100 | 94.3–100 | 77.0–100 | | | | | | |
| Age | | | | | | | | | |
| <18 years | | | | | | | | | |
| Sensitivity, % | 25.7–97.6 | 84.3–100 | 74.3–100 | | | | | | |
| Specificity, % | 80.3–100 | 94.3–100 | 97.8–100 | | | | | | |
| ≥18 years | | | | | | | | | |
| Sensitivity, % ^b | - | - | 62.5–100 | | | | | | |
| Specificity, % b | - | - | 98.9–100 | | | | | | |
| Mixed age | | | | | | | | | |
| Sensitivity, % | 57.5–100 | 77.8–100 | 63.2–100 | | | | | | |
| Specificity, % | 91.8–100 | 94.7–100 | 77.0–100 | | | | | | |
| Setting | | | | | | | | | |
| Inpatient | | | | | | | | | |
| Sensitivity, % | 25.7–95.2 | 98.1–100 | 80.4–100 | | | | | | |
| Specificity, % | 80.3–100 | 94.3–99.4 | 91.5–100 | | | | | | |

| Emergency department/outpatient | | | | | | | |
|---------------------------------|-----------|--------|----------|--|--|--|--|
| Sensitivity, % | 67.8–97.6 | 93–100 | 62.5–100 | | | | |
| Specificity, % | 97.6–99.6 | 96–100 | 97.8–100 | | | | |

"The mariPOC Respi test (n = 4 sub-records) was included in the RSV tests with analytical time >30 min category as the final result is available after 2 hours. The sensitivity and specificity values were not included in the table as there were insufficient data to produce a range of sensitivity or specificity values for relevant patient and setting characteristics.

^bOnly one study assessed an RSV test with analytical time ≤30 min in an adult (≥18 years) only population; therefore, it was not possible to produce a range of sensitivity or specificity values.

RSV, respiratory syncytial virus.

| Table 3. Sensitivity and specificity of RSV tests reviewed under CLIA guidance only. | | | | | | | | | |
|--|-------------------------------|------------|-----------------------------|--|------------------------------------|--|--|---------------------|--|
| Test | Manufacturer | Technology | Analytical time (min) | Sample type | Age of intended patient population | Sensitivity range, % (95% CI) | Specificity range, % (95% CI) | References | |
| Waived | | | | | | | | | |
| BD Veritor System RSV | Becton, Dickinson and Company | Antigen | 10 | Nasopharyngeal swab | <6 years | 67.5 (56.1–77.6) – 97.6 (NR) | 96.8 (91.1–99.3) – 100 (97.0–100) | (45-51) | |
| Alere Binax NOW RSV | Abbott | Antigen | 15 | Nasopharyngeal swab and nasopharyngeal aspirate/wash | <5 years | 41.2 (NR) - 90 (NR) | 93.2 (92.8–93.6) - 100.0 (97–100) | (37, 38, 52- 62) | |
| cobas Influenza A/B & RSV Assay | Roche Diagnostics | Molecular | 20 | Nasopharyngeal swab | Not specified | 94.2 (87.9–97.9) – 100.0 (96.07– 100.0) | 94.29 (86.01– 98.42) – 100 (97.7–100) | (17, 24, 63- 67) | |

| ID NOW RSV ^a | Abbott | Molecular | 13 | Nasopharyngeal swab | <18 years and ≥60 years | 93 (89–96) – 100 (93–100) | 96 (93–98) – 98.0 (95.8–99.1) | (17, 68-70) |
|-----------------------------------|---------|-----------|----|---|-------------------------|---|---|------------------------------------|
| QuickVue RSV | Quidel | Antigen | 15 | Nasopharyngeal swab and nasopharyngeal aspirate and/or nasal wash | ≤18 years | 25.7 (NR) - 90.1 (86.8–93.4) | 98.5 (NR) - 99.5 (92–99) | (50, 71-73) |
| Sofia RSV FIA | Quidel | Antigen | 15 | Nasopharyngeal swab and nasopharyngeal aspirate/wash | <19 years | 74.8 (68.0–80.9) – 100 (82–100) | 86.8 (85.7–87.4) – 100 (95.2–100) | (38, 49, 50, 59, 61, 74- 76) |
| Xpert Xpress Flu/RSV Moderate com | Cepheid | Molecular | 30 | Nasopharyngeal swab and/or nasal swab | Not specified | 66.7 (24.1–94.0) – 98.1 (88.8–99.9) | 98.1 (96.6–99.0) – 100 (99.7–100) | (24, 77-80) |

| | | | | Nasopharyngeal | | | | | |
|-------------|---------------|-------------|-----|-----------------|---------------|-------------------|-------------------|--------------|--|
| 3M Rapid | 3M Health | | | swab and | | 60.0 (38.5–81.5) | 95.6 (93.8–96.9) | | |
| Detection | | Antigen | 15 | nasopharyngeal | ≤21 years | - | _ | (81, 82) | |
| RSV Test | Care | | | aspirate and/or | | 87.3 (83.8–90.1) | 99.6 (98.7–100) | | |
| | | | | nasal wash | | | | | |
| Aries Flu | I | | | Nh1 | | 88.6 (58.3–97.6) | 98.4 (97.7–98.9) | (24 62 64 | |
| A/B & RSV | Luminex | Molecular | 120 | Nasopharyngeal | Not specified | _ | - | (24, 62, 64, | |
| Assay | Corporation | | | swab | | 97.1 (94.4–98.7) | 100.0 (98.8–100) | 83) | |
| BioFire | | | | | | (2.5 (24.5. 01.5) | 00.2 (07.5, 00.0) | | |
| FilmArray | 1: 34/: | M 1 1 | 45 | Nasopharyngeal | N | 62.5 (24.5–91.5) | 98.3 (97.5–98.9) | (24.94.96) | |
| Respiratory | bioMérieux | x Molecular | 45 | swab | Not specified | - | - | (24, 84-86) | |
| 2.1 Panel | | | | | | 99.4 (96.9–99.9) | 100 (97.2–100) | | |
| . | Becton, | | | | | 59 (NR) | 89.5 (NR) | (27.70.50 | |
| Directigen | Dickinson and | Antigen | 15 | Not specified | <20 years | _ | _ | (37, 50, 60, | |
| EZ RSV | Company | | | | | 90 (NR) | 99.5 (97.0–100) | 87-89) | |
| ePlex | GenMark | | | Nagambaran | | 89.6 (80.0–94.8) | 98.9 (94.2–99.8) | | |
| Respiratory | | Molecular | 120 | Nasopharyngeal | Not specified | _ | _ | (90, 91) | |
| Pathogen | Diagnostics | | | swab | | 100 (92.6–100) | 100 (99.8–100) | | |

Panel

| High comple | exity | | | | | | | |
|-------------|---------------|-----------|----------|----------------|---------------|------------------|-------------------|--------------|
| Panther | | | | | | 88.4 (81.1–93.1) | 98.7 (97.0–99.6) | |
| Fusion Flu | | | Not | Nasopharyngeal | | 88.4 (81.1–93.1) | 98.7 (97.0–99.0) | (24, 64, 91- |
| A/B/RSV | Hologic, Inc. | Molecular | reported | swab | Not specified | _ | _ | 94) |
| Assay | | | | | | 100 (NR) | 100 (99.7–100) | |
| | | | | | | 72 2 (44 8 01 0) | 00.4 (06.2, 00.0) | |
| Simplexa | Diasorin | | | Nasopharyngeal | | 73.3 (44.8–91.0) | 99.4 (96.3–99.9) | |
| Flu A/B & | Malandan | Molecular | 60 | 1 | Not specified | _ | _ | (24, 64, 95) |
| RSV | Molecular | | | swab | | 87.0 (74.5–94.2) | 100 (98.9–100) | |


Sensitivity and specificity ranges were not reported for RSV tests with <3 supporting sub-records.

^aThe ID NOW RSV was formerly known as the Alere i RSV.

CI, confidence interval; CLIA, Clinical Laboratory Improvement Amendments; FIA, fluorescence immunoassay; NR, not reported; RSV, respiratory syncytial virus.

FIGURES


Fig. 1. Flow chart summarizing data sources and study selection.



Duplicate articles and ineligible publication types were excluded at the 'Screening' step (n=1297). Where one article reported several relevant sensitivity and specificity values (e.g., when more than one RSV test was studied), then each test was extracted as a sub-record. The 77 included studies corresponded to 133 included sub-records. RSV, respiratory syncytial virus.

Fig. 2. Trends in study design, patient, and setting characteristics in studies included in

712 the review.




- DFA, direct fluorescent antibody test; IFA, immunofluorescence assay; NP, nasopharyngeal;
- POC, point-of-care; RSV, respiratory syncytial virus; rRT-PCR, real-time reverse
- 716 transcription-polymerase chain reaction.


717 Fig. 3. Sensitivity and specificity of RSV tests under CLIA guidance.

718 **A**

720



B



The sensitivity, specificity and analytical time are shown for the RSV tests included in this review that were CLIA-waived (A) and classed as moderate/high complexity (B). RSV, respiratory syncytial virus.